Fasinumab
Fasinumab
Fasinumab (pronounced fa-si-num-ab) is a human monoclonal antibody designed for the treatment of pain, particularly osteoarthritis pain and chronic low back pain. It is developed by Regeneron Pharmaceuticals and Teva Pharmaceutical Industries.
Etymology
The name "Fasinumab" is derived from the Latin word "fasina", meaning "fascinating", and "mab", a common suffix for monoclonal antibodies.
Mechanism of Action
Fasinumab works by targeting and inhibiting the nerve growth factor (NGF), a protein that plays a key role in the regulation of pain signals. By blocking NGF, Fasinumab can potentially reduce pain in patients with osteoarthritis and chronic low back pain.
Clinical Trials
Fasinumab has undergone several clinical trials to evaluate its safety and efficacy. In Phase III trials, it has shown significant improvement in pain and function in patients with osteoarthritis of the knee or hip.
Related Terms
See Also
External links
- Medical encyclopedia article on Fasinumab
- Wikipedia's article - Fasinumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski